Log in or Sign up for Free to view tailored content for your specialty!
Pancreatic Disorders News
Tirzepatide tied to lower odds for diabetic retinopathy, pancreatitis than GLP-1s
Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.
Plozasiran secures FDA breakthrough status for FCS, closing gap with rival olezarsen
The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.
Serum albumin may be a ‘prognostic biomarker’ in acute pancreatitis
Serum albumin levels, specifically hypoalbuminemia, within 24 hours of hospital admission for acute pancreatitis may help predict adverse outcomes and mortality, according to researchers.
Log in or Sign up for Free to view tailored content for your specialty!
Body fat, metabolic changes before pancreatic cancer diagnosis may aid in early detection
In the 36 months prior to diagnosis of pancreatic ductal adenocarcinoma, researchers observed “predominant changes” in patients’ body composition and biochemical markers, which may serve as potential biomarkers for early cancer detection.
Q&A: Petition asks FDA to revise fenofibrate labeling to emphasize no CV outcome benefits
Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.
Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome
Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.
Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome
Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.
Prompt identification of new-onset diabetes may aid early detection of pancreatic cancer
WASHINGTON — An algorithm that uses electronic health record parameters identified glycemic evidence of new-onset diabetes in real time, which could lead to earlier detection of pancreatic ductal adenocarcinoma, according to researchers.
Olezarsen reduces triglycerides, pancreatitis events in familial chylomicronemia syndrome
Monthly olezarsen 80 mg significantly lowered triglyceride levels and also reduced incidence of acute pancreatitis vs. placebo in patients with familial chylomicronemia syndrome, according to a study in The New England Journal of Medicine.
ACG: ‘Early aggressive hydration’ essential to avoid complications in acute pancreatitis
A new ACG guideline published in The American Journal of Gastroenterology underscored that early management “is essential” to prevent complications such as organ failure and pancreatic necrosis in patients with acute pancreatitis.
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read